Literature DB >> 11410504

Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy.

P Birner1, M Schindl, A Obermair, G Breitenecker, G Oberhuber.   

Abstract

PURPOSE: To investigate the impact of expression of hypoxia-inducible factor (HIF)-1alpha on prognosis and on response to chemotherapy in epithelial ovarian tumors. EXPERIMENTAL
DESIGN: Expression of HIF-1alpha protein was studied by immunohistochemistry in 102 specimens of epithelial ovarian cancers, in 50 borderline tumors, and in 20 cystadenomas. Results were correlated with p53, p21, and bcl-2 expression, microvessel density (MVD), apoptotic rate of tumor cells, and survival.
RESULTS: In 68.6% of ovarian cancers and 88% of borderline tumors, expression of HIF-1alpha was observed. There was a significant correlation of HIF-1alpha protein expression and MVD (P < 0.001). HIF-1alpha overexpression alone and MVD showed no impact on survival of cancer patients. Furthermore, the response to platinum-based chemotherapy was independent from HIF-1alpha expression. Expression of HIF-1alpha correlated with apoptotic rate in the majority of cases, especially in low malignant potential tumors. In contrast, in cancer patients with strong expression of HIF-1alpha and p53 protein overexpression, not only a significantly increased MVD (P = 0.032, Mann-Whitney test) but also a significantly shorter overall survival was observed (P < 0.0001, Cox regression). The apoptotic rate was very low in these tumors.
CONCLUSIONS: HIF-1alpha protein overexpression alone has no impact on the prognosis of ovarian cancer. The combination of HIF-1alpha protein overexpression with nonfunctional p53, however, indicates a dismal prognosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11410504

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  93 in total

1.  Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.

Authors:  Bénédicte F Jordan; Matthew Runquist; Natarajan Raghunand; Amanda Baker; Ryan Williams; Lynn Kirkpatrick; Garth Powis; Robert J Gillies
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

2.  Hypoxia inducible factor-1 alpha and multiple myeloma.

Authors:  Archana Bhaskar; Bhupendra Nath Tiwary
Journal:  Int J Adv Res (Indore)       Date:  2016-01-01

Review 3.  Intraoperative imaging in ovarian cancer: fact or fiction?

Authors:  Lucia M A Crane; Marleen van Oosten; Rick G Pleijhuis; Arash Motekallemi; Sean C Dowdy; William A Cliby; Ate G J van der Zee; Gooitzen M van Dam
Journal:  Mol Imaging       Date:  2011-04-26       Impact factor: 4.488

4.  Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.

Authors:  Shivaani Kummar; Mark Raffeld; Lamin Juwara; Yvonne Horneffer; Agnes Strassberger; Deborah Allen; Seth M Steinberg; Annamaria Rapisarda; Shawn D Spencer; William D Figg; Xiaohong Chen; Ismail Baris Turkbey; Peter Choyke; Anthony J Murgo; James H Doroshow; Giovanni Melillo
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

5.  Evaluation of a hypoxia regulated gene panel in ovarian cancer.

Authors:  Amanda F Baker; Scott W Malm; Ritu Pandey; Cindy Laughren; Haiyan Cui; Denise Roe; Setsuko K Chambers
Journal:  Cancer Microenviron       Date:  2015-05-22

6.  Pathological and prognostic significance of hypoxia-inducible factor 1α expression in epithelial ovarian cancer: a meta-analysis.

Authors:  Yue Jin; Haolu Wang; Xiaowen Liang; Jun Ma; Yu Wang
Journal:  Tumour Biol       Date:  2014-05-21

7.  Activation of hypoxia-inducible factor 1 in human T-cell leukaemia virus type 1-infected cell lines and primary adult T-cell leukaemia cells.

Authors:  Mariko Tomita; Gregg L Semenza; Canine Michiels; Takehiro Matsuda; Jun-Nosuke Uchihara; Taeko Okudaira; Yuetsu Tanaka; Naoya Taira; Kazuiku Ohshiro; Naoki Mori
Journal:  Biochem J       Date:  2007-09-01       Impact factor: 3.857

8.  Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410).

Authors:  Yu-Chen Cai; Yong Zou; Yan-Li Ye; Hong-Yi Sun; Quan-Guan Su; Zhi-Xin Wang; Zhao-Lei Zeng; Li-Jian Xian
Journal:  Invest New Drugs       Date:  2009-12-11       Impact factor: 3.850

Review 9.  Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.

Authors:  Daniel Lin; Jennifer Wu
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

Authors:  P de Graeff; A P G Crijns; S de Jong; M Boezen; W J Post; E G E de Vries; A G J van der Zee; G H de Bock
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.